Microba Life Sciences Crescita futura
Future criteri di controllo 5/6
Microba Life Sciences is forecast to grow earnings and revenue by 45.7% and 38.5% per annum respectively. EPS is expected to grow by 54.5% per annum. Return on equity is forecast to be 11.1% in 3 years.
Informazioni chiave
45.7%
Tasso di crescita degli utili
54.5%
Tasso di crescita dell'EPS
| Healthcare crescita degli utili | 25.5% |
| Tasso di crescita dei ricavi | 38.5% |
| Rendimento futuro del capitale proprio | 11.1% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 03 Nov 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 6/30/2027 | 40 | 3 | N/A | 1 | 2 |
| 6/30/2026 | 24 | -19 | N/A | -16 | 2 |
| 6/30/2025 | 18 | -18 | N/A | -13 | 2 |
| 6/30/2024 | 12 | -20 | -20 | -16 | N/A |
| 3/31/2024 | 9 | -19 | -22 | -18 | N/A |
| 12/31/2023 | 7 | -18 | -23 | -20 | N/A |
| 9/30/2023 | 6 | -16 | -19 | -16 | N/A |
| 6/30/2023 | 5 | -13 | -15 | -12 | N/A |
| 3/31/2023 | 5 | -12 | -15 | -12 | N/A |
| 12/31/2022 | 5 | -11 | -14 | -11 | N/A |
| 9/30/2022 | 5 | -11 | -13 | -11 | N/A |
| 6/30/2022 | 5 | -11 | -12 | -10 | N/A |
| 3/31/2022 | 4 | -11 | -11 | -10 | N/A |
| 12/31/2021 | 4 | -11 | -9 | -9 | N/A |
| 9/30/2021 | 4 | -9 | -9 | -8 | N/A |
| 6/30/2021 | 4 | -8 | -8 | -7 | N/A |
| 6/30/2020 | 3 | -7 | -5 | -4 | N/A |
| 6/30/2019 | 2 | -5 | -4 | -4 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: MAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Guadagni vs Mercato: MAP is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: MAP is expected to become profitable in the next 3 years.
Ricavi vs Mercato: MAP's revenue (38.5% per year) is forecast to grow faster than the Australian market (5.7% per year).
Ricavi ad alta crescita: MAP's revenue (38.5% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: MAP's Return on Equity is forecast to be low in 3 years time (11.1%).